NO20082077L - Spirosykliske quinazolinderivater som PDE7-inhibitorer - Google Patents

Spirosykliske quinazolinderivater som PDE7-inhibitorer

Info

Publication number
NO20082077L
NO20082077L NO20082077A NO20082077A NO20082077L NO 20082077 L NO20082077 L NO 20082077L NO 20082077 A NO20082077 A NO 20082077A NO 20082077 A NO20082077 A NO 20082077A NO 20082077 L NO20082077 L NO 20082077L
Authority
NO
Norway
Prior art keywords
spirocyclic
quinazoline derivatives
pde7 inhibitors
compounds
pde7
Prior art date
Application number
NO20082077A
Other languages
English (en)
Inventor
David James Rawson
Nigel Alan Swain
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of NO20082077L publication Critical patent/NO20082077L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Det beskrives forbindelser av formel (I) hvor m er 0, 1 eller 2; C er O, S eller N-CN, R er R, Cl eller CN; A er en C3.6-sykloalkylengruppe valgfritt substituert med en C1.4-alkylgruppe; og B er en enkeltbinding eller en Ci.2-alkylengruppe; eller et farmasøytisk akseptabelt salt, solvat, polymorf eller prodrug derav. Forbindelsene er inhibitorer av PDE7 og har et antall terapeutiske applikasjoner, spesielt for behandling av smerte, spesielt neuropatisk smerte.
NO20082077A 2005-12-02 2008-05-02 Spirosykliske quinazolinderivater som PDE7-inhibitorer NO20082077L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74185405P 2005-12-02 2005-12-02
US79118606P 2006-04-10 2006-04-10
PCT/IB2006/003388 WO2007063391A2 (en) 2005-12-02 2006-11-23 Spirocyclic quinazoline derivatives as pde7 inhibitors

Publications (1)

Publication Number Publication Date
NO20082077L true NO20082077L (no) 2008-06-04

Family

ID=37882213

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082077A NO20082077L (no) 2005-12-02 2008-05-02 Spirosykliske quinazolinderivater som PDE7-inhibitorer

Country Status (22)

Country Link
US (1) US7507742B2 (no)
EP (1) EP1957467A2 (no)
JP (1) JP2009517453A (no)
KR (1) KR101009554B1 (no)
AP (1) AP2008004470A0 (no)
AR (1) AR058266A1 (no)
AU (1) AU2006321349A1 (no)
BR (1) BRPI0619126A2 (no)
CA (1) CA2631535C (no)
CR (1) CR10039A (no)
EA (1) EA200801145A1 (no)
EC (1) ECSP088484A (no)
GT (1) GT200600494A (no)
MA (1) MA30014B1 (no)
ME (1) MEP0408A (no)
NL (1) NL2000336C2 (no)
NO (1) NO20082077L (no)
PE (1) PE20071087A1 (no)
RS (1) RS20080233A (no)
TW (1) TW200732307A (no)
UY (1) UY29979A1 (no)
WO (1) WO2007063391A2 (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0934061B3 (en) 1996-07-24 2015-01-21 Warner-Lambert Company LLC Isobutylgaba and its derivatives for the treatment of pain
EP1879567A1 (en) * 2005-04-28 2008-01-23 Pfizer Limited Amino acid derivatives
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
MX2009010450A (es) * 2007-03-27 2009-11-23 Omeros Corp El uso de inhibidores de la fosfodiesterasa 7 para el tratamiento transtornos del movimiento.
CA2687944A1 (en) * 2007-05-24 2008-11-27 Pfizer Limited Spirocyclic quinazoline derivatives and their use as pde7 inhibitors
SG157299A1 (en) 2008-05-09 2009-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
RU2636614C2 (ru) * 2009-05-19 2017-11-24 Вивия Байотек С.Л. Способы персонализированного медицинского тестирования ex vivo на гематологические новообразования
KR102385359B1 (ko) 2010-11-08 2022-04-11 오메로스 코포레이션 Pde7 억제제를 사용한 중독 및 충동-조절 장애의 치료
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
CU24152B1 (es) 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
US11685745B2 (en) 2017-07-12 2023-06-27 Dart Neuroscience, Llc Substituted benzoxazole and benzofuran compounds as PDE7 inhibitors
CA3264513A1 (en) 2022-08-18 2024-02-22 Mitodicure Gmbh USE OF SUBSTITUTED BENZOFURAN AND BENZOXAZOLE COMPOUNDS FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERCISE INTOLERANCE

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001083772A1 (en) 2000-04-28 2001-11-08 Merck Patent Gmbh Splice variant of camp phosphodiesterase type 7 (pde7a3)
WO2002076953A1 (en) 2001-03-21 2002-10-03 Warner-Lambert Company Llc New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
EP1400244A1 (en) 2002-09-17 2004-03-24 Warner-Lambert Company LLC New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
EP1855686A1 (en) * 2005-03-01 2007-11-21 Pfizer Limited Use of pde7 inhibitors for the treatment of neuropathic pain
WO2006092692A1 (en) * 2005-03-01 2006-09-08 Pfizer Limited Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain

Also Published As

Publication number Publication date
CA2631535C (en) 2010-07-27
US7507742B2 (en) 2009-03-24
NL2000336A1 (nl) 2007-06-05
AP2008004470A0 (en) 2008-06-30
WO2007063391A2 (en) 2007-06-07
TW200732307A (en) 2007-09-01
ECSP088484A (es) 2008-06-30
PE20071087A1 (es) 2007-12-29
BRPI0619126A2 (pt) 2011-09-13
EP1957467A2 (en) 2008-08-20
AU2006321349A1 (en) 2007-06-07
AR058266A1 (es) 2008-01-30
CR10039A (es) 2008-07-10
KR101009554B1 (ko) 2011-01-18
WO2007063391A3 (en) 2007-09-13
RS20080233A (sr) 2009-07-15
KR20080059338A (ko) 2008-06-26
CA2631535A1 (en) 2007-06-07
EA200801145A1 (ru) 2008-10-30
NL2000336C2 (nl) 2007-08-07
GT200600494A (es) 2007-07-06
JP2009517453A (ja) 2009-04-30
US20070129388A1 (en) 2007-06-07
MEP0408A (xx) 2010-02-10
MA30014B1 (fr) 2008-12-01
UY29979A1 (es) 2007-06-29

Similar Documents

Publication Publication Date Title
NO20092033L (no) Nye forbindelser
NO20060665L (no) N-substituerte pyrazolyl-amidyl-benzimidazolyl C-kit inhibitorer
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
NO20064077L (no) Kemokinreseptorantagonister
NO20072371L (no) Kinuklidinderivater og deres anvendelse som muskarine M3-reseptorantagonister
EA200701504A1 (ru) Индолы, пригодные для лечения воспалений
EA200971104A1 (ru) Производные бензимидазола
NO20060664L (no) N-substituerte benzimidazolyl C-kit inhibitorer
EA201001669A1 (ru) Замещенные пиримидин-5-карбоксамиды 281
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
NO20082389L (no) 2,3,4-trifenylimidazolinderivater som inhibitor av interaksjonen mellom P53- og MDM2-proteiner for anvendelse som antikreftmidler
NO20090443L (no) 2-metylmorfolin pyrido-, pyrazo- and pyrimido-pyrimidin derivater
BRPI0411365A (pt) derivados de aminopiridina
NO20055421L (no) Kinolinderivater som fosfodiestrase-inhibitorer
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
EA200801998A1 (ru) ПИРИДИН[3,4-b]ПИРАЗИНОНЫ
NO20091858L (no) Hydrobenzamid derivater som inhibitorer av HSP90
CY1109962T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4,5]δεκαν-2-ονης για τη θεραπεια παχυσαρκιας
SE0400284D0 (sv) Novel compounds
NO20055688L (no) Organiske forbindelser
SE0401345D0 (sv) Therapeutic compounds: Pyridine as scaffold
NO20081888L (no) Triazolforbindelser som lipoksygenaseinhibitorer
BRPI0714885B8 (pt) compostos terapêuticos e seu uso
SE0302192D0 (sv) Novel compounds
EA200801608A1 (ru) Производные бензимидазолонкарбоновой кислоты

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application